高危型HPVDNA联合TCT检测初筛宫颈癌的检验研究
|
摘要
目的探讨高危型人乳头瘤病毒(HPV)DNA联合新柏氏液基细胞学(TCT)检测初筛宫颈癌的价值研究。方法选取2016年1月至2016年12月前来大冶市人民医院就诊的893例妇女作为研究对象。宫颈病理组织学结果以病理组织学为诊断标准,以CIN I、CIN II、CIN III和浸润癌为病理组织学阳性。取TCT采集的宫颈上皮脱落细胞,一份样本同时进行HPV-DNA检测。观察TCT检测结果与病理组织学结果诊断对照、高危型HPV-DNA检测结果与病理组织学结果诊断对照及TCT联合高危型HPV-DNA与病理组织学检测结果结果。结果 TCT检测结果与病理组织学结果阳性符合率为36.65%;高危型HPV-DNA检测结果与病理组织学结果阳性符合率为37.44%;TCT与高危型HPV-DNA联合检测与病理组织学诊断阳性符合率为89.20%。结论高危型HPVDNA联合TCT检测对初筛宫颈癌具有较高的诊断价值。
Objective To investigate the value of high risk human papillomavirus(HPV) DNA combined with Thinprep cytology test(TCT) in the detection of primary cervical cancer. Methods A total of 893 women treated in our hospital from January 2016 to December 2016 were selected as the subjects. The histopathological findings of cervical tissues were taken as the diagnostic criteria, where CIN I, CIN II, CIN III and invasive carcinoma were positive. Cervical epithelial cells were collected by TCT and a sample was detected by HPV-DNA. The results of TCT and pathological findings were compared; the results of high-risk HPV-DNA were compared with the histopathological findings, and the results of TCT combined high-risk HPV-DNA detection and histopathological examination findings were compared. Results The positive coincidence rate between results of TCT and histopathological findings was 36.65%; the positive coincidence rate between high risk HPV-DNA and histopathology results was 37.44%; the positive coincidence rate between TCT combined high-risk HPV-DNA detection and histopathological diagnosis was 89.20%. Conclusions High-risk HPV-DNA combined with TCT has a high diagnostic value in screening cervical cancer.
Objective To investigate the value of high risk human papillomavirus(HPV) DNA combined with Thinprep cytology test(TCT) in the detection of primary cervical cancer. Methods A total of 893 women treated in our hospital from January 2016 to December 2016 were selected as the subjects. The histopathological findings of cervical tissues were taken as the diagnostic criteria, where CIN I, CIN II, CIN III and invasive carcinoma were positive. Cervical epithelial cells were collected by TCT and a sample was detected by HPV-DNA. The results of TCT and pathological findings were compared; the results of high-risk HPV-DNA were compared with the histopathological findings, and the results of TCT combined high-risk HPV-DNA detection and histopathological examination findings were compared. Results The positive coincidence rate between results of TCT and histopathological findings was 36.65%; the positive coincidence rate between high risk HPV-DNA and histopathology results was 37.44%; the positive coincidence rate between TCT combined high-risk HPV-DNA detection and histopathological diagnosis was 89.20%. Conclusions High-risk HPV-DNA combined with TCT has a high diagnostic value in screening cervical cancer.
引文
[1] Wright TC,Stoler MH,Behrens CM,et al.Primary cervical cancer screening with human papillomavirus:end of study results from the ATHENA study using HPV as the first-line screening test[J].Gynecologic Oncology,2015,136(2):189-197.
[2] 王勇,张蔚,黄玥,等.人乳头状瘤病毒DNA联合薄层液基细胞学检查在宫颈癌及早期宫颈病变筛查中的价值[J].中华实用诊断与治疗杂志,2015,29(11):1125-1127.
[3] 徐艺,杨静秀,王玉平.HC2-HPV检测法联合液基细胞学在宫颈癌及癌前病变筛查中的临床意义[J].实用癌症杂志,2016,31(6):1006-1008.
[4] 方向东,赵卫东.二代杂交捕获技术联合液基细胞学检测在宫颈癌早期筛查中的临床应用[J].中国妇幼保健,2015,30(16):2672-2674.
[5] Syrj?nen K.New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors[J].European Journal of Gynaecological Oncology,2017,29(3):205-221.
[6] 王少云,谢东.宫颈液基薄层细胞学检测联合阴道镜在筛查宫颈癌前病变中的价值[J].中国性科学,2015,24(11):36-39.
[7] 毛君辉.宫颈液基细胞学检查联合人乳头状瘤病毒检测在宫颈病变筛查中的价值[J].中国乡村医药,2016,23(2):19-20.
[8] 刘志红,邹艳芬.宫颈液基细胞学检查与高危型HPV检测早期筛查宫颈癌前病变的对比分析[J].现代肿瘤医学,2016,24(8):1269-1271.
[9] Ingledue K,Cottrell R,Bernard A.College womens knowledge perceptions and preventive behaviors regarding human papillomavirus infection and cervical cancer[J].American Journal of Health Studies,2017,19(1):28-34.
[10] 李玉霞,宋晓婕,陈莉,等.宫颈癌筛查中高危型HPV及液基细胞学联合应用的临床价值[J].中国妇幼保健,2015,30(3):479-481.
[11] 樊岩岩,赵俭,左丽,等.HPV联合宫颈液基细胞筛查宫颈病变[J].中国卫生标准管理,2015,6(31):166-167.
[12] 吴红,薛璇.阴道镜联合液基细胞学筛查宫颈病变的诊断价值[J].中国妇幼健康研究,2015,26(6):1275-1277.
[13] 王美英,李芬,杜希林,等.高危型HPVDNA联合TCT检测在宫颈癌初筛中的应用价值[J].国际检验医学杂志,2017,38(5):620-621.
[14] 赵文霞,茅彩英,朱向宇,等.HPV与TCT联合作为宫颈癌初筛的临床意义[J].中国妇幼保健,2014,29(2):187-189.
[15] 喻垚,郭变琴,罗光丽,等.液基细胞学与高危型HPV-DNA联合检测在宫颈病变筛查中的意义[J].检验医学与临床,2015,12(11):1550-1551.
[16] 刘洁.高危型HPV分型检测联合TCT技术在子宫颈癌及其癌前病变筛查中的临床价值.国际医药卫生导报,2016,22(8):1064-1067.
[17] 林雪珊,周全,何春妮.阴道镜和高危型HPV-DNA检测在宫颈不典型病变筛查中的应用[J].中华全科医学,2013,11(6):854-855.
[18] 李沛,许云,杭国琴,等.TCT联合高危型HPV DNA检测在宫颈病变筛查中的诊断价值[J].国际检验医学杂志,2012,33(9):1123-1125.
[2] 王勇,张蔚,黄玥,等.人乳头状瘤病毒DNA联合薄层液基细胞学检查在宫颈癌及早期宫颈病变筛查中的价值[J].中华实用诊断与治疗杂志,2015,29(11):1125-1127.
[3] 徐艺,杨静秀,王玉平.HC2-HPV检测法联合液基细胞学在宫颈癌及癌前病变筛查中的临床意义[J].实用癌症杂志,2016,31(6):1006-1008.
[4] 方向东,赵卫东.二代杂交捕获技术联合液基细胞学检测在宫颈癌早期筛查中的临床应用[J].中国妇幼保健,2015,30(16):2672-2674.
[5] Syrj?nen K.New concepts on risk factors of HPV and novel screening strategies for cervical cancer precursors[J].European Journal of Gynaecological Oncology,2017,29(3):205-221.
[6] 王少云,谢东.宫颈液基薄层细胞学检测联合阴道镜在筛查宫颈癌前病变中的价值[J].中国性科学,2015,24(11):36-39.
[7] 毛君辉.宫颈液基细胞学检查联合人乳头状瘤病毒检测在宫颈病变筛查中的价值[J].中国乡村医药,2016,23(2):19-20.
[8] 刘志红,邹艳芬.宫颈液基细胞学检查与高危型HPV检测早期筛查宫颈癌前病变的对比分析[J].现代肿瘤医学,2016,24(8):1269-1271.
[9] Ingledue K,Cottrell R,Bernard A.College womens knowledge perceptions and preventive behaviors regarding human papillomavirus infection and cervical cancer[J].American Journal of Health Studies,2017,19(1):28-34.
[10] 李玉霞,宋晓婕,陈莉,等.宫颈癌筛查中高危型HPV及液基细胞学联合应用的临床价值[J].中国妇幼保健,2015,30(3):479-481.
[11] 樊岩岩,赵俭,左丽,等.HPV联合宫颈液基细胞筛查宫颈病变[J].中国卫生标准管理,2015,6(31):166-167.
[12] 吴红,薛璇.阴道镜联合液基细胞学筛查宫颈病变的诊断价值[J].中国妇幼健康研究,2015,26(6):1275-1277.
[13] 王美英,李芬,杜希林,等.高危型HPVDNA联合TCT检测在宫颈癌初筛中的应用价值[J].国际检验医学杂志,2017,38(5):620-621.
[14] 赵文霞,茅彩英,朱向宇,等.HPV与TCT联合作为宫颈癌初筛的临床意义[J].中国妇幼保健,2014,29(2):187-189.
[15] 喻垚,郭变琴,罗光丽,等.液基细胞学与高危型HPV-DNA联合检测在宫颈病变筛查中的意义[J].检验医学与临床,2015,12(11):1550-1551.
[16] 刘洁.高危型HPV分型检测联合TCT技术在子宫颈癌及其癌前病变筛查中的临床价值.国际医药卫生导报,2016,22(8):1064-1067.
[17] 林雪珊,周全,何春妮.阴道镜和高危型HPV-DNA检测在宫颈不典型病变筛查中的应用[J].中华全科医学,2013,11(6):854-855.
[18] 李沛,许云,杭国琴,等.TCT联合高危型HPV DNA检测在宫颈病变筛查中的诊断价值[J].国际检验医学杂志,2012,33(9):1123-1125.